Right heart.
Right information.
Right now.

FastCCO algorithm for the Swan-Ganz pulmonary artery catheter
Trusted performance, faster response.

What do you get when the trusted performance of continuous thermodilution meets the rapid response of arterial pressure-based cardiac output (APCO)? Accurate CO and SV parameters every 20 seconds.

The trusted name in pulmonary artery catheters now delivers hemodynamic insights even faster with the new FastCCO algorithm – exclusively available for the Swan-Ganz catheter.

When it comes to comprehensive right heart monitoring, every second counts.

Answers in seconds.
With the FastCCO algorithm.

The FastCCO algorithm fuses thermodilution from the thermal filament of the Swan-Ganz catheter and APCO from the PA waveform. This allows the FastCCO algorithm to deliver CO and SV status 70% faster than current Swan-Ganz pulmonary artery catheter technologies.

Smart. Innovation.
With insights into patient perfusion.

FastCCO algorithm is part of the latest software on HemoSphere advanced monitoring platform. Also available for the modular HemoSphere platform is ForeSight Elite tissue oximetry system, which continuously monitors oxygen saturation, noninvasively.

The HemoSphere platform gives you a comprehensive view of tissue oximetry and advanced hemodynamics on one monitor so you can ensure your patient is adequately perfused.

Individualized fluid management.
With faster flow parameters.

The FastCCO algorithm’s flow parameter readings every 20 seconds enable uninterrupted observation of patient responses to fluid challenges and passive leg raise tests, and allow intuitive adjustment of fluid management.

The fluid responsiveness test screen on the HemoSphere platform allows clinicians to quickly assess preload responsiveness by tracking changes in SV, SVI, CO or CI in response to a fluid challenge.
A proven legacy.
With strong clinical support.

Studies in patients with cardiogenic shock have shown that the use of pulmonary artery catheters is associated with a decreased length of hospital stay, decreased pulmonary morbidity and no increased risk of in-hospital mortality.¹

Engage in learning.
With comprehensive training and education.

Visit the Edwards Lifesciences clinical education portal for a suite of online educational tools, video content and in-depth training to support your successful adoption of the Swan-Ganz pulmonary artery catheter with the new FastCCO algorithm.

Contact your Edwards representative or visit Edwards.com/gb/Swan to learn more.

<table>
<thead>
<tr>
<th>Model</th>
<th>Description</th>
<th>Size (F)</th>
<th>CCO</th>
<th>SvO₂</th>
<th>SV</th>
<th>SVR</th>
<th>RVEF</th>
<th>RVEDV</th>
<th>VIP port</th>
</tr>
</thead>
<tbody>
<tr>
<td>774F75</td>
<td>CCOMbo RVEDV (CCO + SvO₂ + RVEDV)</td>
<td>7.5 X X X X X X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>777F8</td>
<td>CCOMbo RVEDV/VIP (CCO + SvO₂ + RVEDV + VIP lumen)</td>
<td>8 X X X X X X X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

References

For professional use. For a listing of indications, contraindications, precautions, warnings, and potential adverse events, please refer to the Instructions for Use (consult eifu.edwards.com where applicable).

Edwards devices placed on the European market meeting the essential requirements referred to in Article 3 of the Medical Device Directive 93/42/EEC bear the CE marking of conformity

Edwards, Edwards Lifesciences, the stylized E logo, FastCCO, ForeSight, ForeSight Elite, HemoSphere, Swan, and Swan-Ganz are trademarks of Edwards Lifesciences Corporation or its affiliates. All other trademarks are the property of their respective owners.

© 2021 Edwards Lifesciences Corporation. All rights reserved. PP--EU-2257 v1.0

Edwards Lifesciences • Route de L’Etraz 70, 1260 Nyon, Switzerland • edwards.com